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In this issue, Raca et al1 present two cases of childhood apraxia of
speech (CAS) arising from microdeletions of chromosome 16p11.2.
They propose that comprehensive phenotypic profiling may assist in
the delineation and classification of such cases. To complement this
study, we would like to report on a third, unrelated, child who
presents with CAS and a chromosome 16p11.2 heterozygous deletion.
We use genetic data from this child and his family to illustrate how
comprehensive genetic profiling may also assist in the characterisation
of 16p11.2 microdeletion syndrome.
A number of chromosome 16p11.2 aberrations have been reported
in the recent literature, including gross rearrangements and sub-
microscopic (o1Mb) deletions and duplications with incomplete
penetrance and variable expressivity and in a heterozygous form.2 In
general, microdeletions appear to be more penetrant than their
respective duplications.3 The ‘typical’ 16p11.2 deletion encompasses
539 kb (from chromosome position 29.5–30.1Mb, GRCh37/hg19)
and 24 genes, but a smaller adjacent distal or ‘atypical’ deletion
(between chromosome positions 28.7 and 28.95Mb, GRCh37/hg19)
has also been reported, as have novel anomalies outside of these
specified regions.2,4,5 Individuals have been described with deletions
spanning both these regions4,6 and families have been observed to
carry both rearrangement types.7 It has been suggested that proximal
rearrangements may be associated with developmental impairments
and distal variations correlated with altered body mass index,2
although developmental delays and speech and language impair-
ments appear to be a common feature of individuals with various
anomalies across this chromosome band.8–10
Screens of clinical cohorts indicate that chromosome 16p11.2
rearrangements are observed at a frequency of 0.3–0.7% in patients
with various developmental impairments including autistic disorder
(eg, Weiss et al11), developmental delay (eg, Shinawi et al3), epilepsy12
and schizophrenia (eg, McCarthy et al13). Deletions are also observed
in apparently healthy individuals, at a similar frequency to clinical
cohorts,5 and while the majority of cases appear to be de novo,
inherited imbalances of this region are not uncommon.
Recently there has been a drive to define a core clinical phenotype
of the 16p11.2 microdeletion syndrome. In a retrospective screen of
9773 individuals referred for microarray testing, Rosenfeld et al8
found that 77 carried chromosome 16p11.2 anomalies (45 deletions,
32 duplications, 0.78%). A detailed review of 18 patients found
that the most consistent clinical manifestations in these individuals
were intellectual impairment and speech and language delays.8
These findings were supported by a similar study that included
7400 patients who had undergone array comparative genomic
hybridisation (array-CGH) testing in a clinical context, 45 of whom
carried 16p11.2 anomalies (27 deletions, 18 duplications, 0.6%).3
Phenotypic characterisation of 27 individuals also found that all had
speech and language delays and cognitive impairment.3 Other predomi-
nant features of 16p11.2 syndrome include dysmorphism, macrocephaly
and autistic disorders.3,4,8,14 However, all of these features have
been disputed and it is likely that ascertainment bias will affect the
conclusions of many studies, particularly those that focus upon single
cases. Thus, the characterisation of the relationships between genetic
aberration and clinical presentation is ongoing and will require
further, more refined, studies with detailed investigations of this
chromosome region and consistent phenotyping of affected
individuals.
The child described here was originally assessed for the presence of
FOXP2 (OMIM #605317) mutations and rearrangements, as part of
an earlier screening project,15 as disruptions of this gene have been
implicated in rare cases of severe speech and language disorder.16
Although no FOXP2 mutations were identified in the child, we
discovered a deletion of chromosome 16p11.2. The child is a second-
born male child of unrelated and healthy parents of European
(Caucasian) descent. His early development was normal until the
age of 1.5 years, when there was evidence of a social withdrawal. He
was referred following concerns regarding his speech and language
development and received a diagnosis of developmental verbal
dyspraxia, also known as CAS, and pervasive developmental
disorder not otherwise specified (PDD-NOS) according to DSM-
IV.17 On assessment with the Vineland Adaptive Behaviour Scales,18
he showed a remarkable impairment in language and communi-
cation. At age 14, he scored at an age equivalent of 3 years and 3
months in the communication domain, with a major impairment in
the expressive subdomain. He also displayed stereotypic movements
and behavioural disturbances with self-aggressive episodes. He did not
have hearing or ocular problems and had normal height and weight.
The patient showed macrocephaly and peculiar facial features, such as
heavy eyebrows with mild synophris, down-slanting palpebral fissures,
hypertelorism, short philtrum, carp shaped mouth and full lips.
He had brachydactyly and single crease bilaterally. His parents were
clinically normal with no family history of speech delay, autistic
disorders or mental retardation.
Peripheral blood samples were collected from the proband and
his parents, and DNA extracted according to standard procedures.19
To identify genomic imbalances, DNA samples were hybridised to
Agilent 244K and Agilent 4 44K arrays (Agilent Technologies Inc.,
Santa Clara, CA, USA) for the proband and his parents, respectively.
The array-CGH was completed as part of an assessment of 36 children
with specific language impairment, PDD-NOS and autism spectrum
disorders (ASD). Image data were extracted using Agilent Feature
Extraction software version 8.5 (Agilent Technologies Inc.) and
analysed using Agilent CGH Analytics software version 3.4 (z-score
method setting) (Agilent Technologies Inc.). The reference genomic
DNA samples used throughout the study were from the same
consented individuals, one male and one female. We estimate that
the mean resolution of the Agilent 244K arrays is B40 kb.
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We identified a de novo chromosome 16p11.2 deletion in the
proband’s sample (see Figure 1). The minimal region affected by this
deletion spans from chromosome position 29 652 999 to 30 199 351
(GRCh37/hg19) and encompasses 28 Refseq genes, thus coinciding
with the ‘proximal’ type reported in the literature.2 The presence
of speech and language abnormalities, macrocephaly and PDD in
this child coincides with previously reported core phenotypes of
chromosome 16p deletions.1,3,4,8,14 The CAS diagnosis of this case
provides further support to the findings of Raca et al1 and their
theory as to the importance of proximal chromosome 16p11.2
abnormalities in CAS. It would thus be of interest to fully assess
the CAS in this child using the Madison Speech Assessment Protocol
and other relevant speech batteries suggested by Raca et al.20,21
Using the array-CGH data, we catalogued all observed imbalances
that spanned four or more consecutive oligonucleotide probes with
values outside the log10 Cy-dye threshold ratios for the proband. We
excluded any region that had been observed repeatedly either in
control data deposited in the Database of Genomic Variants (DGV)22
or within our own sample sets, and small imbalances that mapped to
regions without noted reference genes or mRNAs. This approach
allowed us to identify an additional novel duplication of chromosome
6q22.31, which occurred both in the proband and in his clinically
normal mother. This duplication has a minimal region from
chromosome position 123 527 545 to 124 311 813 (GRCh37/hg19)
and does not overlap significantly with any known CNVs in the DGV.
The duplication covers two genes: the entire coding region of TRDN
(OMIM #603283) (triadin), a ryanodine-sensitive calcium channel
expressed in cardiac and skeletal muscle,23 and the first exon of
NKAIN2 (OMIM #609758) (sodium/potassium-transporting ATPase
subunit beta-1-interacting protein 2 isoform 2), a transmembrane
protein. Truncation of NKAIN2 has been described in patients
with developmental delay24 and complex neurological impairment.25
All other events found in the patient overlapped with those reported
in the DGV. A full list of events can be found in Supplementary
Table 1.
Thus we hypothesise that the inherited chromosome 6q22.31
duplication may compound the presence of the de novo 16p11.2
deletion, leading to the observed clinical phenotype in this patient.
As most researchers focus solely on the chromosome 16p abnormality,
or choose to exclude inherited CNVs, most cases of ‘dual CNV
disorder’ such as this will have been missed in the literature. In an
attempt to identify similar cases, we performed a PubMed search for
‘16p11.2’ that matched 130 articles (August 1990–February 2012).
Fifty of these manuscripts described the characterisation of 16p11.2
anomalies, of which only nine explicitly reported information
regarding concurrent CNVs.7,10,12,14,26–30 When limiting our search
to cases with typical proximal (29.5–30.1Mb) 16p11.2 anomalies,
we were unable to identify any 16p11.2 cases reported to co-occur
with NKAIN2 CNVs. Across the nine studies available, the only regions
that were consistently reported across multiple studies as secondary
CNVs in 16p11.2 patients were 15q11.2 (Prader–Willi syndrome
region, found in 2 of 31 16p11.2 patients studied in Bachmann-
Gagescu et al10 and 1 of 427 autistic individuals studied in Marshall
et al28), 15q13.2 (found in 2 of 138 16p11.2 duplication carriers
studied in Jacquemont et al27 and 1 of 427 autistic individuals studied
in Marshall et al28) and 22q11.2 (DiGeorge syndrome critical region,
found in 1 of 31 16p11.2 patients studied inBachmann-Gagescu
et al10 and 1 of 36 autistic individuals studied in Davis et al30).
Interestingly, these recurrent secondary CNVs align with regions
known to be involved in autism and developmental delays.31–33
When we widened our search to include novel chromosome
16p11.2 CNVs outside of the typical region (28.0–31.4Mb), we did
find one study that documented cases with co-occurring chromosome
16p11.2 and 6q22.31 abnormalities.29 This study, by Sanders et al,29
investigated 1124 individuals with autism and their unaffected family
members (2248 parents and 872 sibs) and identified several recurrent
copy number events associated with autism, including rearrangements
of 16p11.2, both within and outside the ‘typical’ region. As part of
their Supplementary data, the authors published full lists of all high-
confidence CNVs found in samples passing quality control. These
Figure 1 Chromosome 16p11.2 deletion and chromosome 6q22 duplication found in proband with CAS. The chromosome 16 deletion is shown in the left
panel and the chromosome 6 duplication in the right panel (the minimally deleted and duplicated regions are indicated by the green and red double-ended
arrows, respectively. The proband’s DNA was examined using an Agilent 244 K array and the parents on the lower density 44K arrays.
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included lists of rare CNVs that did not overlap more than 50%
with a CNV present at41% frequency in the DGV29 (Supplementary
Table S8). Using these Supplementary data, we were able to identify
seven autistic probands who carried concurrent 16p11.2 (five
duplications and two deletions) and NKAIN2 (six duplications and
one deletion) anomalies, all inherited from healthy parents (Table 1).
However, all of these events were small (o50 kb) and none
overlapped with those observed in our patient. No 16p11.2 events
were found to be concurrent with TRDN CNVs. Furthermore, the
chromosome 16p11.2 anomalies identified by Sanders et al29 in these
concurrent cases were all outside of the typical region and, on review
of the DGV, we noted that those involving the SULT1A1 (OMIM
#171150) gene overlapped significantly with regions of common
variation (Table 1). Similarly, the NKAIN2 anomalies were intronic to
the RefSeq NKAIN2 consensus sequence, or overlapped with common
CNVs in the DGV (Table 1). However, it is worth noting that we
observed a mRNA, BC035062, that is annotated to include an exon
contained within the common ‘intronic’ duplication, suggesting these
events may affect a splice variant.
The patient we describe in this letter carries the typical 16p11.2
loss co-occurring with a further 6q22.31 duplication, both of
which are distinct from those described above. The latter does not
overlap significantly with noted DGV variants. However, further
mining of the Sanders et al29 Supplementary data identified three
healthy individuals carrying apparently identical 6q22.31 duplications
(a father and son and another father) (Supplementary Table S8).
Thus the 6q22.31 duplication in our case may represent a very rare
CNV with little independent effect, but we cannot rule out a
modifying role in combination with the 16p11.2 loss, particularly in
view of the gene content. The 6q22.31 duplicated region in our
patient encompasses all of the coding regions of TRDN and the first
exon of NKAIN2. TRDN codes for a muscle-specific protein, deletion
of which leads to cardiac arrhythmia.34 Although primarily expressed
in cardiac tissue, this gene is also expressed in skeletal muscle, where it
is involved in the regulation of resting calcium levels.35 NKAIN2 is a
transmembrane protein with four homologues (NKAIN1–4), all of
which are highly conserved and have brain-specific expression.36
Interestingly, it is the only gene in common with the smaller 6q22.31
CNV regions described above. The cellular functions of the NKAIN
proteins are unknown but they have been shown to localise and interact
with the plasma membrane protein ATP1B1. Drosophila dNKAIN
mutants show decreased co-ordination and temperature-sensitive
paralysis.36 Microdeletions in NKAIN2 have previously been reported
as rare events contributing to the risk of schizophrenia37 and Attention
Table 1 Probands with Concurent 16p11.2 and 6q22.31 CNVs from the Sanders et al29 Study (a) Chromosome 16p11.2 anomalies and
(b) Concurrent chromosome 6q22.31 anomalies
Individual
16p11.2
start (hg18)
16p11.2
end (hg18)
16p11.2
size
16p11.2
State
16p11.2
Inheritance 16p11.2 Genes Intronic/Exonic?
DGV frequency
rangea
Average DGV
frequencyb
(a)
Our patient 29 560 500 30 106 852 546 352 Deletion De novo SPN to CORO1A
(inclusive)
Exonic, 30 genes 0.00–0.00 0.00
11009.p1 28 521 466 28 528 253 6787 Duplication Paternal SULT1A1 Exons 1-7 (of 8) 0.03–0.30 0.17
11087.p1 28 522 302 28 528 253 5951 Duplication Paternal SULT1A1 Exons 1-7 (of 8) 0.03–0.30 0.17
11096.p1 28 521 466 28 528 253 6787 Deletion Maternal SULT1A1 Exons 1-7 (of 8) 0.03–0.30 0.30
11229.p1 31 386 212 31 396 534 10322 Duplication Maternal TGFB1I1 Exons 1-11 (of 11) 0.00–0.00 0.00
11246.p1 30 497 961 30 502 245 4284 Deletion Paternal ZNF785 Exon 3 (of 3) 0.00–0.00 0.00
11996.p1 28 522 302 28 528 253 5509 Duplication Unsure SULT1A1 Exons 1-7 (of 8) 0.03–0.30 0.17
12961.p1 28 522 744 28 528 253 5951 Duplication Paternal SULT1A1 Exons 1-7 (of 8) 0.03–0.30 0.17
(b)
Individual 6q22.31
start (hg18)
6q22.31
end (hg18)
6q22.31
size
6q22.31
State
6q22.31
Inheritance
6q22.31 Genes Intronic/Exonic? DGV frequency
rangea
Average DGV
frequencyb
Our patient 123 581 324 124 201 824 620 500 Duplication Maternal TRDN, NKAIN2 Exons 1-41 (of 41), 0.00–0.00 0.00
Exon 1 (of 6)
11009.p1 124 477 640 124 510 591 32951 Duplication Maternal NKAIN2 Exon 2 of
BC035062 mRNA
0.001–0.029 0.01
11087.p1 124 477 640 124 510 591 32951 Duplication Maternal NKAIN2 Exon 2 of
BC035062 mRNA
0.001–0.029 0.01
11096.p1 124 479 205 124 510 591 31386 Duplication Paternal NKAIN2 Exon 2 of
BC035062 mRNA
0.001–0.029 0.01
11229.p1 124 480 321 124 510 591 30270 Duplication Maternal NKAIN2 Exon 2 of
BC035062 mRNA
0.001–0.029 0.01
11246.p1 124 477 640 124 510 591 32951 Duplication Paternal NKAIN2 Exon 2 of
BC035062 mRNA
0.001–0.029 0.01
11996.p1 124 959 283 124 961 396 2113 Deletion Unsure NKAIN2 Intronic 0.00–0.00 0.00
12961.p1 124 477 640 124 510 591 32951 Duplication Paternal NKAIN2 Exon 2 of
BC035062 mRNA
0.001–0.029 0.01
Abbreviation: DGV, database of genomic variants.
aDGV range frequency gives the frequency range of deletions or duplications (as appropriate) in all DGV studies that included at least 30 individuals and the CNV is reported (NB: this includes
populations other than European).
bFrequency DGV gives the average frequency of deletions or duplications (as appropriate) reported in studies including at least 30 European individuals in the DGV.
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Deficit/ Hyperactivity Disorder (ADHD),38 and variants within this
gene have been associated with neuroticism.39
Taking all of this information into consideration, we believe that
the clinical presentation of chromosome 16p11.2 deletion cases may
be modulated by the presence of additional genomic imbalances,
such as the inherited duplication of chromosome 6q22.31 observed
in our case. Researchers of developmental disorders have proposed
a dual CNV model at other loci,33,40–42 as well as compound
heterozygotes with a CNV-mediated deletion of one allele and non-
synonymous mutation of the other (mixed genomic disorders).43,44
The genetic background, of course, extends beyond CNVs and,
as genetic technologies advance, we predict that a whole-genome
view will allow the elucidation of many combinatorial factors.
For example, a recent study extended the dual CNV model to
incorporate rare point mutations across common functional path-
ways, where an ASD proband was identified with both a de novo
mutation of FOXP1 (OMIM #605515) and an inherited mutation of
CNTNAP2 (OMIM #604569).45 The validity of this model and the
significance of concurrent CNVs can only be tested by the consistent
and detailed description of CNV cohorts in a whole-genome context.
This is especially true for studies such as ours, which involve only a
single patient. We would therefore urge researchers characterising
chromosome abnormalities to consider, and to explicitly report, the
anomalies in the context of whole genome copy number variation and
genomic cataloguing. Advances in genetic technology mean that there
is no longer a need to consider genomic imbalances in isolation,
particularly in case reports. We suggest that the capture of complete
genomic contexts, alongside detailed phenotypic profiling, will allow
us to develop a better understanding of the variability of the
chromosome 16p11.2 phenotype and may assist in the delineation
of a core clinical phenotype.
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